Recent research is challenging the long-held assumption that the benefits of GLP-1 receptor agonists for joint health are driven solely by weight reduction. New findings suggest that these therapies may improve knee osteoarthritis through metabolic mechanisms that are independent of weight loss.
A study published on February 9 examined the effects of semaglutide, a GLP-1 receptor agonist widely used for metabolic conditions, on patients with knee osteoarthritis. Researchers discovered that the drug may contribute to cartilage repair and joint function improvement through pathways unrelated to weight reduction.
Eric Topol, physician-scientist and founder and director of the Scripps Research Translational Institute, highlighted the broader implications of these findings. According to Topol, many of the health benefits associated with GLP-1 therapies appear to extend well beyond their effects on body weight.
Evidence supporting this concept comes from both preclinical mouse models and a randomized clinical study. These data suggest that semaglutide may improve knee osteoarthritis not only by reducing mechanical stress on joints but also by influencing metabolic and inflammatory pathways involved in cartilage health.
The findings are based on the STEP 9 clinical trial, a large international study involving 407 participants across 61 clinical sites in 11 countries. The trial focused on adults with moderate knee osteoarthritis accompanied by severe knee pain and obesity, defined as a body mass index (BMI) of 30 kg/m² or higher.
Over a 68-week treatment period, participants receiving weekly injections of 2.4 mg semaglutide experienced an average body weight reduction of 10.5%, equivalent to approximately 25 pounds (11 kilograms). At baseline, the average body weight among participants was about 239 pounds (108.6 kilograms).
However, weight loss was not the only significant outcome. Participants also reported meaningful reductions in pain intensity. Pain levels were measured using the validated Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). On a 0-100 pain scale, patients treated with semaglutide experienced an average reduction of 41.7 points, compared with a 27.5-point reduction in the placebo group.
Functional improvements were also substantial. Approximately 50% of patients receiving semaglutide achieved clinically meaningful improvements in physical function, compared with 29% in the placebo group. These improvements translated into better mobility and enhanced ability to perform everyday activities.
The study population reflected typical characteristics of patients with knee osteoarthritis. The average participant age was 56 years, and 81.6% of participants were female. At baseline, all individuals reported severe knee pain, with an average standardized pain score of 70.9.
Throughout the study, all participants received guidance on lifestyle modifications, including calorie-restricted diets and physical activity programs, alongside the assigned treatment.
Semaglutide demonstrated a generally favorable safety profile. The medication was gradually titrated over a 16-week period to reach the target 2.4 mg dose. By the end of the study, nearly 90% of participants in the treatment group were still maintaining this dose.
Gastrointestinal symptoms were the most common side effects and the leading cause of treatment discontinuation. Nevertheless, only 6.7% of patients in the semaglutide group discontinued treatment due to adverse events, compared with 3% in the placebo group. The incidence of serious adverse events was similar between the two groups.
Importantly, the significance of the study goes beyond confirming that weight loss can relieve joint pain—a relationship already well documented in medical literature. The new insight is that metabolic improvements may occur independently of weight loss, suggesting that GLP-1 receptor agonists could support joint health through multiple biological pathways.
For patients living with both obesity and knee osteoarthritis, these findings are particularly encouraging. Previous research has shown that a weight reduction of approximately 5% can already lead to noticeable improvements in pain and function. The STEP 9 trial indicates that semaglutide combined with lifestyle interventions may help patients achieve and even exceed this threshold.
Despite the promising results, questions remain about the durability of the benefits. Earlier studies have shown that after discontinuing semaglutide therapy, patients often regain a significant portion of the lost weight—sometimes up to two-thirds within a year. Whether improvements in joint pain and function persist after treatment cessation remains unclear.
The study also has several potential limitations. Because participants in the treatment group experienced significant weight loss, they may have been more likely to recognize that they were receiving the active medication, which could influence subjective pain reporting.
Nevertheless, objective improvements were also observed. Participants treated with semaglutide demonstrated improvements in stiffness, physical function, and walking performance, including longer distances in the six-minute walk test.
During the study period, the use of pain medications declined in both groups, with a greater reduction observed in the semaglutide group. However, researchers noted that patients in this group had higher baseline acetaminophen use, which may partially explain the difference.
Overall, the findings highlight the possibility that GLP-1 receptor agonists may provide broader therapeutic benefits beyond metabolic disease management. By influencing metabolic regulation, inflammation, and cartilage health, these therapies may represent a promising future direction for the treatment of knee osteoarthritis.
Post time: 2026-03-09